Journal of Clinical and Experimental Ophthalmology
Open Access

Jose María Ruiz-Moreno

Publications

• Research Article
  Role of Systemic Anti-Tumor Necrosis Factor Alpha Treatment in the Reduction of Proliferative Vitreoretinopathy
  Author(s): Laura Jimeno, Maria Rosa Sanabria, Ivan Fernandez-Bueno, Lior Lipski, Anat Loewenestein, Amandio Rocha-Sousa, Cristina Ferreira-Sousa, Alfredo Adan, Marina Mesquida, Salvatore Di Lauro, Jose María Ruiz-Moreno, Ignacio Flores, Marta Fernandez, Alfredo Garcia Layana, Jose Carlos Pastor and Anna SalaLaura Jimeno, Maria Rosa Sanabria, Ivan Fernandez-Bueno, Lior Lipski, Anat Loewenestein, Amandio Rocha-Sousa, Cristina Ferreira-Sousa, Alfredo Adan, Marina Mesquida, Salvatore Di Lauro, Jose María Ruiz-Moreno, Ignacio Flores, Marta Fernandez, Alfredo Garcia Layana, Jose Carlos Pastor and Anna Sala
  
  Objective: Proliferative vitreoretinopathy (PVR) is still one of the most serious complications of rhegmatogenous retinal detachment (RRD) because there is no effective treatment or prophylaxis. Tumor necrosis factor α (TNFα) has been implicated in the development of PVR. Thus, the blockade of this factor could reduce or prevent the onset of PVR. However, systemic treatment with anti-TNFα has some risks and side effects, and the use of these drugs in this situation is not yet justified. Therefore we sought an indirect approach to determine if systemic anti-TNFα provided any protection against the development of PVR after RRD surgery. We attempted to estimate the rate of RRD and PVR in patients who were treated systemically with anti-TNFα drugs because of autoimmune diseases and who also had surgically-treated RRD. Methods: .. View More»
  DOI: 10.4172/2155-9570.1000464

  Abstract PDF

Relevant Topics